Literature DB >> 30088917

Routes to Potentially Safer T1 Magnetic Resonance Imaging Contrast in a Compact Plasmonic Nanoparticle with Enhanced Fluorescence.

Luke Henderson, Oara Neumann, Caterina Kaffes, Runmin Zhang, Valeria Marangoni, Murali K Ravoori, Vikas Kundra, James Bankson, Peter Nordlander, Naomi J Halas.   

Abstract

Engineering a compact, near-infrared plasmonic nanostructure with integrated image-enhancing agents for combined imaging and therapy is an important nanomedical challenge. Recently, we showed that Au@SiO2@Au nanomatryoshkas (NM) are a highly promising nanostructure for hosting either T1 MRI or fluorescent contrast agents with a photothermal therapeutic response in a compact geometry. Here, we show that a near-infrared-resonant NM can provide simultaneous contrast enhancement for both T1 magnetic resonance imaging (MRI) and fluorescence optical imaging (FOI) by encapsulating both types of contrast agents in the internal silica layer between the Au core and shell. We also show that this method of T1 enhancement is even more effective for Fe(III), a potentially safer contrast agent compared to Gd(III). Fe-NM-based contrast agents are found to have relaxivities 2× greater than those found in the widely used gadolinium chelate, Gd(III) DOTA, providing a practical alternative that would eliminate Gd(III) patient exposure entirely. This dual-modality nanostructure can enable not only tissue visualization with MRI but also fluorescence-based nanoparticle tracking for quantifying nanoparticle distributions in vivo, in addition to a near-infrared photothermal therapeutic response.

Entities:  

Keywords:  contrast agent; fluorescence; magnetic resonance; nanomatryoshka; photostability

Mesh:

Substances:

Year:  2018        PMID: 30088917     DOI: 10.1021/acsnano.8b03368

Source DB:  PubMed          Journal:  ACS Nano        ISSN: 1936-0851            Impact factor:   15.881


  7 in total

1.  Comparison of ferumoxytol- and gadolinium chelate-enhanced MRI for assessment of sarcomas in children and adolescents.

Authors:  Florian Siedek; Anne M Muehe; Ashok J Theruvath; Raffi Avedian; Allison Pribnow; Sheri L Spunt; Tie Liang; Crystal Farrell; Heike E Daldrup-Link
Journal:  Eur Radiol       Date:  2019-12-16       Impact factor: 5.315

Review 2.  Leveraging the interplay of nanotechnology and neuroscience: Designing new avenues for treating central nervous system disorders.

Authors:  Elizabeth S Smith; Joshua E Porterfield; Rangaramanujam M Kannan
Journal:  Adv Drug Deliv Rev       Date:  2019-03-04       Impact factor: 15.470

3.  Functionalized Gold Nanoparticles as Contrast Agents for Proton and Dual Proton/Fluorine MRI.

Authors:  Maria Şologan; Francesco Padelli; Isabella Giachetti; Domenico Aquino; Mariangela Boccalon; Gianpiero Adami; Paolo Pengo; Lucia Pasquato
Journal:  Nanomaterials (Basel)       Date:  2019-06-13       Impact factor: 5.076

Review 4.  NIR-I Dye-Based Probe: A New Window for Bimodal Tumor Theranostics.

Authors:  Fan Zheng; Xueyan Huang; Jipeng Ding; Anyao Bi; Shifen Wang; Fei Chen; Wenbin Zeng
Journal:  Front Chem       Date:  2022-03-23       Impact factor: 5.221

Review 5.  Multifunctional magnetic iron oxide nanoparticles: an advanced platform for cancer theranostics.

Authors:  Shengzhe Zhao; Xujiang Yu; Yuna Qian; Wei Chen; Jianliang Shen
Journal:  Theranostics       Date:  2020-05-15       Impact factor: 11.556

6.  Gold Nanoparticles Mediate Improved Detection of β-amyloid Aggregates by Fluorescence.

Authors:  Pedro Jara-Guajardo; Pablo Cabrera; Freddy Celis; Mónica Soler; Isadora Berlanga; Nicole Parra-Muñoz; Gerardo Acosta; Fernando Albericio; Fanny Guzman; Marcelo Campos; Alejandra Alvarez; Francisco Morales-Zavala; Marcelo J Kogan
Journal:  Nanomaterials (Basel)       Date:  2020-04-06       Impact factor: 5.076

7.  Dendrimer-modified gold nanorods as a platform for combinational gene therapy and photothermal therapy of tumors.

Authors:  Lili Ye; Yaoming Chen; Jizong Mao; Xiaotian Lei; Qian Yang; Chunhui Cui
Journal:  J Exp Clin Cancer Res       Date:  2021-09-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.